CD20单克隆抗体的制备及治疗B细胞淋巴瘤研究进展

目的:制备CD20的单克隆抗体(mAb),并探讨对治疗B细胞淋巴瘤的作用机制。方法:构建重组表达质粒pGEX-4T-1-CD20和pET-32a-CD20。以融合蛋白CD20-GST为免疫源免疫BALB/c雌性小鼠制备(mAb)。结果:CD20-GST和CD20-His蛋白在大肠杆菌中可高效表达,经纯化后可获得高纯度的CD20蛋白。结论:成功制备高纯度CD20蛋白并以此为抗原制备了1株能够稳定分泌抗人CD20的鼠单mAb的杂交瘤细胞株BD11F4。临床试验结果表明,抗CD20单克隆抗体既可单独应用,亦可作为放射性同位素或细胞毒制剂的载体,其疗效显著,且使用安全,副反应小。许多研究报道已阐明了抗CD20单克隆抗体治疗B细胞淋巴瘤的几种可能的效应机制。目前,人们正致力于探索一些新的治疗策略以期提高这种疗法的特异性,减少其非特异性的毒副作用。

Preparation of Anti-human CD20 Monoclonal Antibody and Recent Advance in Anti-CD20 Monoclonal Antibody Therapy in B-cell Lymphoma

Objective:To prepare its monoclonal antibody and discuss on mechanism of B-cell lymphoma.Methods:The CD20 gene was amplified from human histoleucocyte by RT-PCR and were cloned into expression vectors and generate pGEX-4T-1-CD20(CD20-GST) and pET-32a-CD20(CD20-His).Immunized the BALB/c mice with purified CD20-GST to prepare the monoclonal antibody.Results:CD20-GST and CD20-His were highly expressed in E-coli and got the CD20 protein with high purity.Conclusions:We prepared the CD20 fusion protein with high purity.The mAb against CD20 with high titer and specificity has been obtained,which lays the foundation for investigation of CD20 function and diagnosis and therapy of non-Hodgkin lymphoma(NHL).The results of clinical trials had showed that antiCD20 monoclonalantibodies,which could be utilized in either unmodified form or as carrier for radioisotopes or cytotoxic agents,have significant effects and can be administ rated safely with minimum side effects.